$3.25 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Neoleukin

Neoleukin Therapeutics, Inc., formerly Aquinox Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is focused on the development and commercialization of computationally-designed protein therapeutics to address unmet medical needs in immuno-oncology, inflammation, and autoimmunity. Its computational platform allows it to design new de novo proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its lead program, NL-201, is a computationally-designed de novo protein therapeutic. NL-201 is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. NL-201 is designed for use as a single-agent or in combination with complementary therapeutic modalities.

Stock Analysis

last close $3.25
1-mo return -33.9%
3-mo return -53.6%
avg daily vol. 207.57T
52-week high 14.9
52-week low 3.25
market cap. $163M
forward pe -
annual div. -
roe -32.8%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 62.5%

Subscribe now for daily local and international financial news